Table 3.

Changes in histological grading of Helicobacter pylori infection before and after treatment

	Eradication (Group HpE)*	Placebo (Group Hp+)†	p Value
Antral gastritis
Baseline	4 (1–6)	4 (1–6)	0.28
End of treatment	1 (0–4)	3 (1–6)	<0.0001
Corpus gastritis
Baseline	3 (0–6)	3 (0–6)	0.56
End of treatment	1 (0–4)	4 (0–6)	<0.0001
Antral atrophy
Baseline	0 (0–2)	0 (0–3)	0.24
End of treatment	0 (0–3)	0 (0–3)	0.63
Corpus atrophy
Baseline	0 (0–1)	0 (0–1)	0.54
End of treatment	0 (0–1)	0 (0–1)	0.85
Antral intestinal metaplasia
Baseline	0 (0–2)	0 (0–3)	0.88
End of treatment	0 (0–3)	0 (0–3)	0.91
Corpus intestinal metaplasia
Baseline	0 (0–2)	0 (0–1)	0.18
End of treatment	0 (0–1)	0 (0–1)	0.45

All values are median (range).

*Within HpE group comparison between baseline and end of treatment: antral gastritis: p<0.0001, suggesting significant resolution of gastritis after H pylori eradication; corpus gastritis: p<0.0001, suggesting significant resolution of gastritis after H pylori eradication; antral atrophy: p = 0.07; corpus atrophy: p = 0.32; antral intestinal metaplasia: p = 0.11; corpus intestinal metaplasia: p = 1.0.

†Within Hp+ group comparison between baseline and end of treatment: antral gastritis: p = 0.15; corpus gastritis: p<0.0001, suggesting significant increase in severity of gastritis; antral atrophy: p = 0.28; corpus atrophy: 0.32; antral intestinal metaplasia: p = 0.053; corpus intestinal metaplasia: p = 0.32.